Melatonin oral gel(Spherium Biomed SL)

Burn disease, which is a sequel of skin burn injuries, is a common cause of complications and the development of associated pathologies. This study aimed to assess the effects of burn disease on the lungs and their correction with melatonin. We used a standard skin 14-day burn model in Wistar rats. During burn progression, phase changes in metabolism were noted from a hypometabolic phase in the first 4 days to a hypermetabolic phase starting on Day 5. By Day 14, the energy metabolism had normalized to the control level. In experimental melatonin burn treatment, a hypermetabolic response was noted during the first 3 days. By Day 10, the ventilatory response decreased below the baseline level, and by Day 14, it did not significantly differ from that in the control group. Morphological changes in the lungs of rats with burn injuries were characterized by structural alterations, such as reduced functional activity, decreased air permeability, and suppression of gas exchange processes. In rats receiving melatonin alongside burn injury, most morphological lung indicators remained at control levels. We conclude that melatonin treatment accelerates healing and reduces complications associated with burn injuries.

A recent case study reported a non-24 h sleep-wake disorder in a patient with myotonic dystrophy type 1 (DM1). Research on intrinsic circadian rhythm sleep-wake disorders (CRSWDs) in DM1 patients is though lacking. This study utilized actigraphy to ascertain the presence of CRSWDs in DM1 patients and establish a comparison with healthy control subjects.

Thirty-three patients with genetic diagnosis of DM1 and 33 age- and sex-matched healthy control subjects wore an actigraph and filled out a sleep diary for two consecutive weeks. Sleep, light exposure, and nonparametric measures were computed from actigraphic data.

DM1 patients exhibit poorer sleep quality and delayed sleep-wake episodes as well as reduced daylight exposure compared to healthy control subjects. Importantly, 3 DM1 patients (9.1 %) had a delayed sleep phase disorder and 3 DM1 patients had an irregular sleep-wake rhythm disorder (ISWRD) (9.1 %) whereas no control subject exhibited a CRSWD. DM1 patients with an ISWRD presented lower inter-daily stability (IS) (0.16 vs. 0.44, p < 0.05) and relative amplitude (RA) (0.36 vs. 0.79, p < 0.01) as well as higher intra-daily variability (IV) (1.22 vs. 0.79, p < 0.05) than DM1 patients with a normal sleep phenotype. DM1 patients with CRSWDs were more likely to exhibit excessive daytime sleepiness (EDS) than those with a normal sleep phenotype (83.3 % vs. 37.0 %, p < 0.05).

Core clinical implications are the need to systematically screen DM1 patients for CRSWDs and apply a multimodal chronotherapy (sleep hygiene, timed light, and melatonin). Recognizing and treating CRSWDs can help address significant sleep disturbances, like EDS.